// App-Quantinova.ai

2675 : Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study

Researchers

Presenter

  • Lydia Wunderle

Principal Investigators

  • Susanne Badura

  • Fabian Lang

  • Andrea Wolf

  • Eberhard Schleyer

  • Hubert Serve

  • Nicola Goekbuget

  • Heike Pfeifer

  • Gesine Bug

  • Oliver G. Ottmann

Medical Centers

  • Department of Hematology/Oncology, Goethe-University Hospital Frankfurt, Frankfurt Am Main, Germany

  • Carl-von-Basedow-Klinikum, Merseburg, Germany

  • Department of Hematology/Oncology, Goethe-University Hospital Frankfurt, Frankfurt Am Main, Germany

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Hematological malignancies

  • Acute myelocytic leukemia

  • Acute Leukemia

  • Hyperglycemia

  • Solid malignancies

  • Mucositis

  • Sepsis

  • T-cell acute lymphoblastic leukemia

  • Gastric antral vascular ectasia

Biomarkers

  • Phosphatase and tensin homolog

  • Phosphatidylinositol 3-kinase

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Phosphorylated 4E-binding protein 1

  • Hemoglobin A1c

  • Ubiquitin A-52 Residue Ribosomal Protein Fusion Product 1

Drug/Treatment

  • Phosphatidylinositol

  • Rapacan

  • BEZ235

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved